ArticleAmerican journal of translational research2026
Hormone receptor status score is negatively correlated with adverse pathological features and serves as an independent prognostic factor in endometrial carcinoma.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the effect of estrogen and progesterone receptor status score on the prognosis of endometrial cancer (EC) patients.
methodsWe chose 187 endometrial cancer patients hospitalized in The Affiliated Hospital of Southwest Medical University between March 2021 and March 2023. The histologic score (H score) and the Allred score were used to evaluate and analyze their correlation with clinical pathological parameters and prognosis.
resultsThe hormone receptor status score was negatively correlated with lymph node metastasis (LNMs), differentiation degree, depth of invasion (DOI), and the clinical stage (P<0.05). The hormone receptor status score was significantly higher in the survival group compared to that in the dead group (P<0.05). According to multivariate logistic regression analysis, the hormone receptor status score was identified as an independent protective factor for endometrial cancer patient prognosis (P<0.05).
conclusionThe hormone receptor status score has a definite correlation with LNMs, DOI, differentiation degree, and clinical stage in EC patients, and is related to prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.